Germany: ArchiMed takes majority stake in Zyto

French private equity healthcare specialist ArchiMed has acquired a majority stake in cancer diagnostics group Zyto. Financial terms have not been disclosed. Zyto’s three operating companies – Zytomed, ZytoVision and 42 Life Sciences – provide doctors with diagnostic tools to understand the genetic changes that occur in individual patients’ tumours. The approach permits precision medical…

You must be a HMI Subscriber to view this content. Please log in or subscribe below.

Subscribe Now »